Professor Joseph Witztum discusses the evidence to support targeting apolipoprotein C-III with antisense therapies such as single stranded RNA, DNA molecules or siRNA, or with monoclonal antibodies, to reduce plasma triglycerides in order to lower the associated enhanced risk of acute pancreatitis and potentially cardiovascular risk.